Tobin Schilke - 15 Feb 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Terri McDowell, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Feb 2022
Net transactions value
-$39,035
Form type
4
Filing time
17 Feb 2022, 19:49:18 UTC
Previous filing
04 Feb 2022
Next filing
17 Mar 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $29,917 -2,241 -3.3% $13.35 65,815 15 Feb 2022 Direct F1
transaction RVNC Common Stock Tax liability $9,118 -683 -1% $13.35 65,132 15 Feb 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 16,500 shares. The RSA vests in three equal annual installments from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan.")) on each vesting date.
F2 Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 5,000 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date.